chloral hydrate has been researched along with Cyanosis in 4 studies
Cyanosis: A bluish or purplish discoloration of the skin and mucous membranes due to an increase in the amount of deoxygenated hemoglobin in the blood or a structural defect in the hemoglobin molecule.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chloral hydrate was used in 356 patients and intranasal dexmedetomidine in 376." | 1.72 | Intranasal dexmedetomidine: the ideal drug for sedation in the pediatric echo lab? ( Bartz, P; Frommelt, PC; Lavoie, J; Saudek, DE; Schaal, A; Shreve, S; Walbergh, D, 2022) |
| "Chloral hydrate is a safe and effective agent for sedation of children with known or suspected congenital heart disease who are undergoing echocardiography in the outpatient cardiology clinic." | 1.29 | Safety and efficacy of chloral hydrate sedation in children undergoing echocardiography. ( Ingall, CG; Martin, GR; Napoli, KL, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saudek, DE | 1 |
| Walbergh, D | 1 |
| Bartz, P | 1 |
| Shreve, S | 1 |
| Schaal, A | 1 |
| Lavoie, J | 1 |
| Frommelt, PC | 1 |
| Ghaffar, S | 1 |
| Haverland, C | 1 |
| Ramaciotti, C | 1 |
| Scott, WA | 1 |
| Lemler, MS | 1 |
| Napoli, KL | 1 |
| Ingall, CG | 1 |
| Martin, GR | 1 |
| Granoff, DM | 1 |
| McDaniel, DB | 1 |
| Borkowf, SP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Increasing Depth of Dexmedetomidine and Propofol Anesthesia on Upper Airway Morphology in Children With History of Obstructive Sleep Apnea[NCT01344759] | Phase 4 | 60 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is the count of the number of patients who needed an artificial airway. (NCT01344759)
Timeframe: During MRI and until recovery room discharge - approximately 30-250 minutes
| Intervention | Number of artifical airway events (Number) |
|---|---|
| Mild OSA and Dexmedetomidine | 0 |
| Mild OSA and Propofol | 1 |
| Moderate OSA and Dexmedetomidine | 1 |
| Moderate OSA and Propofol | 1 |
| Severe OSA and Dexmedetomidine | 2 |
| Severe OSA and Propofol | 5 |
The Obstructive Index is a count of the obstructive apnea events per hour of sleep (NCT01344759)
Timeframe: During MRI and until recovery room discharge - approximately 30-250 minutes
| Intervention | Apnea events/hour of sleep (Mean) |
|---|---|
| Mild OSA and Dexmedetomidine | 4.2 |
| Mild OSA and Propofol | 3.0 |
| Moderate OSA and Dexmedetomidine | 8.0 |
| Moderate OSA and Propofol | 8.0 |
| Severe OSA and Dexmedetomidine | 16.7 |
| Severe OSA and Propofol | 17.1 |
The respiratory disturbance index is a count of respiratory disturbance events per hour of sleep. (NCT01344759)
Timeframe: During MRI and until recovery room discharge - approximately 30-250 minutes
| Intervention | respir.disturbance events/hr of sleep (Mean) |
|---|---|
| Mild OSA and Dexmedetomidine | 5.1 |
| Mild OSA and Propofol | 3.2 |
| Moderate OSA and Dexmedetomidine | 8.8 |
| Moderate OSA and Propofol | 7.1 |
| Severe OSA and Dexmedetomidine | 16.6 |
| Severe OSA and Propofol | 25.2 |
The patient's oxygen saturation on room air. (NCT01344759)
Timeframe: During MRI and until recovery room discharge - approximately 30-250 minutes
| Intervention | percentage of SpO2 (Mean) |
|---|---|
| Mild OSA and Dexmedetomidine | 87.2 |
| Mild OSA and Propofol | 88.0 |
| Moderate OSA and Dexmedetomidine | 86.3 |
| Moderate OSA and Propofol | 89.0 |
| Severe OSA and Dexmedetomidine | 84.0 |
| Severe OSA and Propofol | 88.0 |
The primary outcome measures will be the cross sectional area of the pharyngeal airway of the patients measured at two levels soft palate (nasopharyngeal) and base of the tongue (retroglossal). Magnetic resonance images of the airway were obtained during low (1 mcg/kg/hr) and high (3 mcg/kg/hr) doses of DEX or low (100 mcg/kg/m) and high (200 mcg/kg/m) doses of Propofol. All were administered through an intravenous (IV) catheter. (NCT01344759)
Timeframe: during MRI within first 10 minutes of scanning
| Intervention | mm^2 (Median) | |||
|---|---|---|---|---|
| Low Dose Sedative, Nasopharyngeal measurement | High Dose Sedative, Nasopharyngeal measurement | Low Dose Sedative, Retroglossal measurement | High dose sedative, Retroglossal measurement | |
| Dexmedetomidine | 178.5 | 235.4 | 120.9 | 120.5 |
| Propofol | 239.9 | 201.6 | 115.1 | 108.1 |
4 other studies available for chloral hydrate and Cyanosis
| Article | Year |
|---|---|
Intranasal dexmedetomidine: the ideal drug for sedation in the pediatric echo lab?
Topics: Child; Chloral Hydrate; Cyanosis; Dexmedetomidine; Heart Diseases; Humans; Hypnotics and Sedatives; | 2022 |
Sedation for pediatric echocardiography: evaluation of preprocedure fasting guidelines.
Topics: Arrhythmias, Cardiac; Child, Preschool; Chloral Hydrate; Cyanosis; Echocardiography; Fasting; Heart | 2002 |
Safety and efficacy of chloral hydrate sedation in children undergoing echocardiography.
Topics: Adolescent; Age Factors; Ambulatory Care; Blood Pressure; Child; Child, Preschool; Chloral Hydrate; | 1996 |
Cardiorespiratory arrest following aspiration of chloral hydrate.
Topics: Asphyxia; Chloral Hydrate; Cyanosis; Electroencephalography; Heart Arrest; Humans; Infant; Male; Res | 1971 |